INSIGHTS on Developing Antibody-Drug Conjugates
Clinicians and patients alike know that traditional cancer treatments beat up the person as much as the cancer. Success arises only if the treatment kills the cancer before the patient. For decades, researchers sought solutions that attacked only the cancer, not healthy tissue.
The Promise of Safer and More Effective Cancer Treatments Still Faces Obstacles
In the past few years, some of the most promising and targeted new treatments come from antibody-drug conjugates (ADCs), in which an antibody delivers the drug to specific cancerous cells. Like all medications, though, ADCs have their pros and cons, but this arsenal of cancer treatments keeps expanding.
Click here to read more about Developing Antibody-Drug Conjugates.